Last reviewed · How we verify
NCT03927287: FPSAR
Prognostic Role of Free Psa Ratio at Biochemical Recurrence After Radical Treatments for Prostate Cancer
trial testing Free PSA ratio test in patients after definitive treatment for localized prostate cancer in Metastasis in 822 participants. Completed in 10 April 2019.
30 December 2018
Quick facts
| Lead sponsor | Rabin Medical Center |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 822 |
| Start date | 1 January 2018 |
| Primary completion | 30 December 2018 |
| Estimated completion | 10 April 2019 |
| Sites | 1 location across Canada |
Drugs / interventions tested
- Free PSA ratio test in patients after definitive treatment for localized prostate cancer
Conditions studied
- Metastasis — all drugs for Metastasis →
- Castration-resistant Prostate Cancer — all drugs for Castration-resistant Prostate Cancer →
- Death — all drugs for Death →
Sponsor
Rabin Medical Center
Who can join
18 and older, male only, with Metastasis or Castration-resistant Prostate Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Measurement of Free PSA ratio in patients after definitive radical treatment for prostate cancer, and assessment of whether post-treatment free PSA ratio can function as a biomarker for advanced disease in prostate cancer patients.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Can post-treatment free PSA ratio be used to predict adverse outcomes in recurrent prostate cancer?
Goldberg H, Glicksman R, Woon D, Hoffman A, et al · · 2021 · cited 4× · PMID 32926761 · DOI 10.1111/bju.15236
Verify or expand the search:
- PubMed search for NCT03927287
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Metastasis
Currently open trials in the same condition.
- NCT06787014 — Resection of the Primary Tumor vs. Systemic Treatment Alone for Patients With Small Intestinal Neuroendocrine Tumors and · recruiting
- NCT06863272 — A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Re · Phase 1, PHASE2 · recruiting
- NCT07040657 — Comparison of Two-Position and Four-Position Cervical Injection Techniques for Sentinel Lymph Node Mapping in Endometria · NA · recruiting
- NCT07154563 — Rapid Assessment of Sentinel Lymph Node Metastasis Status Using a Pan-CK-targeting NIR-II Fluorescent Probe in Breast Ca · recruiting
- NCT06362369 — A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy · Phase 1, PHASE2 · recruiting
Other Rabin Medical Center trials
Trials by the same sponsor.
- NCT06837909 — Transversus Abdominis Plane Block Versus Wound Infiltration for Pulmonary Function Preservation Following Laparoscopic L · NA · recruiting
- NCT06951399 — Tracking T-Cell Responses to Evaluate Pembrolizumab Effectiveness in Advanced Non-Small Cell Lung Cancer · Phase 2 · not yet recruiting
- NCT07208240 — Tb-PSMA-I&T Radionuclide Before Radical Prostatectomy in Patients With Locally Advanced Prostate Cancer - TbeforePROST T · Phase 1, PHASE2 · recruiting
- NCT06931119 — Aprepitant in the Management of Immune Checkpoint Inhibitors Pruritus in Solid Cancer Patients · Phase 1 · not yet recruiting
- NCT06966427 — Prospective Evaluation of a Dose Guidance System for People With Diabetes Initiating Basal Insulin or Using Insulin Inje · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03927287 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Rabin Medical Center
- Last refreshed: 25 April 2019
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03927287.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing